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Abstract
OBJECTIVE: To explore the effects of evodiamine
on ovarian cancer cells and the mechanisms under-
lying such effects.
METHODS: Human ovarian cancer cells HO-
8910PM were treated with evodiamine at 0, 1.25,
2.5, and 5 μM for 1-4 d. 3-(4,5-Dimethiylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
was used to detect the growth inhibition rate of
evodiamine-treated HO-8910PM cells. The cell cy-
cle was observed via propidium iodide (PI) stain-
ing. Apoptosis induction was assessed via Annex-
in V-fluorescein isothiocyanate/propidium iodide
(Annexin V-FITC/PI) double staining assay. To veri-
fy the mechanism of apoptosis, caspase-depen-
dent apoptotic pathway-related protein was de-
tected by Western blot analysis. The expression lev-
els of mitogen-activated protein kinase (MAPK)
and/or phosphatidylinositol-3-kinase (PI3K)/pro-
tein kinase B (Akt) pathway-related proteins were
also investigated.
RESULTS: Evodiamine significantly inhibited the
proliferation of HO-8910PM cells in a dose- and
time-dependent manner. Evodiamine induced G2/
M arrest with an increase of cyclin B1 level, and pro-
moted cell apoptosis with a decrease of B cell lym-
phoma/lewkmia-2 (Bcl-2) and an increase of
Bcl-2-associated X protein (Bax) level. In addition,
evodiamine treatment led to the activation of cas-
pase-8, caspase-9, and caspase-3 and the cleavage
of poly (ADP-ribose)-polymerase (PARP). Evodi-
amine targeted the MAPK and/or PI3K/Akt path-
ways by reducing the expression and activity of
PI3K, Akt, and extracellular signal-regulated kinase
mitogen-activated protein kinase (ERK1/2 MAPK)
and the activity of p38 MAPK.
CONCLUSION: Evodiamine can inhibit the growth
of ovarian cancer cells by G2/M arrest and intrinsic
and extrinsic apoptosis. In addition, evodiamine-in-
duced PI3K/Akt, ERK1/2 MAPK, and p38 MAPK sig-
naling may be involved in cell death.
© 2016 JTCM. All rights reserved.
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INTRODUCTION
Ovarian cancer is one of the most common gynecolog-
ic cancers, next to cervical and endometrial cancers.
However, the mortality rate of ovarian cancer is the
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highest among the above-mentioned cancer types. The
5-year survival rate of ovarian cancer is poor despite
the availability of chemotherapy and routine surgery.
Tumor recurrence and metastasis are considered as the
major reasons for poor clinical outcome and ovarian
cancer-related deaths.1 Therefore, developing effective
measures against ovarian cancer is critical.
Evodiamine is a quinolone alkaloid isolated from a tra-
ditional Chinese medicinal plant, Wuzhuyu (Fructus
Evodiae Rutaecarpae). Evodiamine has pharmacological
properties, including anti-anoxic, antinociceptive and
vasorelaxant properties. Recent studies show that evodi-
amine can inhibit various tumors, including human
pancreatic tumor cell SW1990,2 human thyroid cancer
cell ARO,3 human melanoma cell A375-S2,4 and hu-
man cervical cancer cell HeLa5 through cycle arrest and
apoptosis. In addition, evodiamine has been reported
to inhibit the invasion and metastasis of cancer cells in-
cluding human breast cell MDA-MB-2316 and colon
26-L5 cell.7 Evodiamine shows no toxic effects on nor-
mal peripheral blood mononuclear cells and normal
human mammary epithelial cell line H184B5H5/
M10.3,8 Therefore, evodiamine is a promising candidate
for further development as an antitumor agent. Howev-
er, the effect of evodiamine on ovarian cancer cell is
still unclear. In the study, we examined the effect of
evodiamine on the growth of human ovarian cancer
cell line HO-8910PM in vivo.
MATERIALS ANDMETHODS
Chemicals and reagents
Evodiamine was purchased from Sigma (Louis, MO,
USA), and its purity was determined to be approxi-
mately 99% by high performance liquid chromatogra-
phy. Evodiamine was dissolved in dimethylsulfoxide
(DMSO) to create a stock solution and was diluted in
RPMI-1640 medium before the experiments. The
DMSO concentration in the cell culture medium was
below 0.1%. The RPMI-1640 medium and penicillin/
streptomycin were purchased from Gibco (Shanghai,
China), whereas the fetal bovine serum (FBS) was pur-
chased from Hyclone (Beijing, China). Trypsin-ethyl-
enediaminetetraacetic acid, phosphate buffer solution
(PBS) and bicinchoninic acid protein assay kit were
purchased from KeyGen Biotech (Nanjing, China),
whereas DMSO and 3-(4, 5-dimethylthiazol-2yl)-2,
5-diphemyltetrazolium bromide (MTT) were from Sig-
ma (Shanghai, China). The cell cycle detection kit was
purchased from Multi Biotech (Hangzhou, China). An-
nexin V/PI apoptosis detection kit was purchased from
BD Biosciences (San Diego, CA, USA). The B cell lym-
phoma/lewkmia-2 (Bcl-2), Bcl-2-associated X protein
(Bax), caspase 3, caspase 8, caspase 9, cleaved cas-
pase-9, poly (ADP-ribose)-polymerase (PARP), phos-
phatidylinositol 3-kinase (PI3K), phospho-PI3K
(p-PI3K), phospho-protein kinase B (p-Akt), extracel-
lular signal-regulated protein kinases (ERK1/2), p38,
phospho-p38 (p-p38), stress-activated protein kinase/
c-Jun N-terminal kinase (SPAK/JNK), and phos-
pho-SPAK/JNK (p-SPAK/JNK) antibody were ob-
tained from Cell Signaling Technology (Beverly, MA,
USA). Cyclin B1, phospho-cell division cycle 2
(p-Cdc2) (Tyr15) and Akt were from Abcam (Cam-
bridge, UK). Cdc2 and phospho-ERK1/2 (p-ERK1/2)
antibody were from Antibody Revolution, Inc. (San Di-
ego, CA, USA). Horseradish peroxidase (HRP)-conju-
gated secondary antibodies against mouse IgG and rab-
bit IgG were from Merck Millipore (Billerica, MA,
USA). Enhanced chemiluminescent kits were obtained
from Fude Biotech (Hangzhou, China).
Cell culture
The human ovarian epithelial cancer cell line
HO-8910PM which was purchased from Keygen Bio-
tech (Nanjing, China), was cultured in RPMI-1640
medium supplemented with 10% FBS, 100 U/mL pen-
icillin, and 100 μg/mL streptomycin in a humid atmo-
sphere incubator containing 95% room air and 5%
CO2 at 37 ℃ . The cells were harvested for the experi-
ment under logarithmic growth conditions.
Cell viability assay
The cell viability was measured using the MTT assay,
as previously described.9 The HO-8910PM cells were
seeded in 96-well plates (Nest Biotech Co., Ltd.,
Shanghai, China) at a density of 5000 cells/well. After
12 h, the cells were treated with different concentra-
tions of evodiamine for the indicated time. 10 μL
MTT (5 mg/mL) was supplemented into each well
and incubated at 37 ℃ for 4 h. Subsequently, the
MTT solution was removed and replaced by 150 μL
DMSO with the absorbance at 490 nm. The wave-
length (A490) was measured by a microplate reader
from Bio-Rad Laboratories, Inc. (Hercules, CA, USA).
The rate of cell growth inhibition was calculated as fol-
lows: Inhibitory rate = [A490 (control) - A490]/ A490
(control) × 100%.
Flow cytometry analysis of the cell cycle distribution
After treatment with or without evodiamine for 24 h,
the cells were harvested, washed, and fixed with 70%
cold ethanol for 24 h at 4 ℃ . The cells were washed
twice with cold PBS and stained with 500 μL propidi-
um iodide (PI) solution in the dark for 30 min at room
temperature. The cells were analyzed using fluores-
cence-activated cell sorter (FACSCalibur) flow cytome-
ter from Becton, Dickinson and Company (East Ruth-
erford, NJ, USA).
Flow cytometry detection of apoptotic cells
After treatment with or without evodiamine for 48 h,
the adherent and suspended cells were collected and
washed with cold PBS. Annexin V-fluorescein isothio-
cyanate/propidium iodide (Annexin V-FITC/PI) apop-
tosis detection kit was used according to the manufac-
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turer's protocol. 5 μL Annexin V-FITC and 5 μL PI
were added to the cells, which were incubated at room
temperature for 20 min in the dark prior to analysis.
Western blot assay
Western blot assay was performed to analyze the levels
of protein expression. After treatment with or without
evodiamine for 24 h, the all cells were collected and
lysed in RIPA buffer containing a protease inhibitor
cocktail. Cellular proteins (60 μg) from each sample
were separated by 8% to 12% SDS-polyacrylamide gel
electrophoresis. The separated fragments were trans-
ferred to 0.22 μm polyvinylidene fluoride membranes,
which were blocked with 5% skim milk in Tris-buff-
ered saline with 0.1% Tween-20 (TBS-T) for 1 h at
room temperature. The membranes were incubated
and allowed to react with primary antibodies overnight
at 4℃ . After washing with TBS-T buffer thrice (for
3 min to 10 min each time), the membranes were incu-
bated with HRP-conjugated secondary antibodies and
diluted in 5 mL 0.5% blocking buffer for 1 h. After
washing twice with TBS-T buffer for 10 min, the
bound antibodies were detected using enhanced chemi-
luminescence reagents. Chemiluminescent signals were
captured using the FluorChem FC2 System (Alpha
Inootech Corporation, San Leandro, CA, USA). The
expression level of each protein was quantified using Al-
phaview software with glyceraldehyde-3-phosphate de-
hydrogenase (GADPH) as the loading control.
Statistical analysis
Triplicate experiments with triplicate samples were per-
formed. The SPSS 16.0 (SPSS Inc., Chicago, IL, USA)
software package was used for statistical analyses. The
data were expressed as the mean ± standard error of
mean (SEM). Comparisons were made between the
groups using Student's t-test or one-way analysis of vari-
ance. P values of < 0.05 were accepted as significant.
RESULTS
Evodiamine inhibited the growth of ovarian cancer
cells and induced cell cycle arrest at G2/M phase.
The cell proliferation was measured by MTT assay. Af-
ter incubation with evodiamine for 24 h, the growth in-
hibition was not obvious (P > 0.05). The significant in-
hibitory effect of evodiamine on HO-8910PM cell
growth was observed at 48 h and persisted for 96 h
(P < 0.05) (Figure 1). The IC50 values in 48, 72, and
96 h were 3.94, 2.16, and 1.66 μM, respectively.
To gain insight into the mechanism of evodiamine cell
growth inhibition, the cell cycle distribution was as-
sessed by PI staining after evodiamine treatment for 24
h. The number of cells during each phase was signifi-
cantly different (P < 0.0001) between the control and
experimental groups. As shown in Figure 2A and 2B,
the G2/M percentage was dramatically increased from
19.7% in the control group to 33.9% , 56.0% , and
66.0% in the groups treated with evodiamine at 1.25,
2.5, and 5 μM, respectively. The G0/G1 percentage
was markedly reduced from 65.3% in the control
group to 43.0%, 19.9%, and 6.4% in the groups treat-
ed with evodiamine at 1.25, 2.5, and 5 μM, respective-
ly. To explore the G2/M arrest mechanism caused by
evodiamine, Western blot analysis was performed to
measure the expressions of cell cycle-regulating mole-
cules. Compared with the control group, the expres-
sion of cyclin B1 was significantly increased (Figure
2C) in the evodiamine-treated groups.
Evodiamine induced apoptosis via extrinsic and
intrinsic apoptosis pathways in HO-8910PM cells
To determine the effects of evodiamine on apoptosis,
the cells were treated with evodiamine for 48 h. Annex-
in V-FITC/PI double staining assay was used to deter-
mine apoptotic cells. Figures 3A and 3B showed that
the HO-8910PM cells treated with evodiamine dis-
played much higher apoptosis rates than the cells in
the control group, and the increase in apoptosis rate
was dose dependent (P < 0.05). The underlying mecha-
nism was subsequently explored. After evodiamine
treatment for 24 h, caspase-3 activation and caspase
substrate PARP cleavage were detected by Western blot
analysis (Figure 3E). The activation of upstream pro-
teins was further examined. The results showed that
the activation of the extrinsic pathway-related protein
caspase-8, the activation of the intrinsic pathway
through the decrease of Bcl-2, the increase of Bax, and
the activation of caspase-9 were initiated after the evo-
diamine treatment (Figures 3C and 3D).
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Figure 1 Evodiamine inhibited the proliferation of HO-8910PM cells
Cells were treated with various concentrations of evodiamine (0 μM to 10 μM) for 1 day to 4 day. The cell viability was measured
using MTT assay. MTT: 3-(4,5-Dimethiylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. Compared with the control group, aP < 0.05,
bP < 0.001.
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Figure 2 Evodiamine induced G2/M arrest in HO-8910PM cells
A: after exposure to evodiamine (at 0 μM to 5 μM) for 24 h, cell cycle analysis was performed by flow cytometry. A1: 0 μM evodi-
amine; A2: 1.25 μM evodiamine; A3: 2.5 μM evodiamine; A4: 5 μM evodiamine. G1 was the DNA pre-synthetic phase; S was the
DNA synthesis stage; and G2 was the DNA post-synthetic phase. B: After evodiamine treatment (0 μM to 5 μM) for 24 h, the ly-
sates were analyzed for the level of cyclin B1 byWestern blot assay. C: The data represent the percentage of cells in each phase of
the cell cycle. 1: 0 μM evodiamine; 2: 1.25 μM evodiamine; 3: 2.5 μM evodiamine; 4: 5 μM evodiamine; GAPDH: glyceralde-
hyde-3-phosphate dehydrogenase.
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Figure 3 Evodiamine induced apoptosis in HO-8910PM cells through the
extrinsic and intrinsic apoptosis pathways
A: measurements of apoptosis. A1: 0 μM evodiamine; A2: 1.25 μM evodi-
amine; A3: 2.5 μM evodiamine; A4: 5 μM evodiamine. After exposure to
evodiamine (at 0 μM to 5 μM) for 48 h, apoptosis was detected using the
Annexin V/PI double staining assay. Lower left: normal cells; upper left:
necrotic cells; lower right: early apoptotic cells; upper right: late apoptot-
ic cells. B: the proportion of apoptotic cells after evodiamine treatment
were quantified and illustrated; Compared with the group, the signifi-
cance levels in the treated groups were aP < 0.05 and bP < 0.01. C-E: cells
were treated with evodiamine (at 0 μM to 5 μM) for 24 h. The cell lysates
were analyzed for the expression of caspase-3, caspase-8, caspase-9,
PRAP, Bax, and Bcl-2 by Western blot assay. 1: 5 μM evodiamine; 2: 2.5
μM evodiamine; 3: 1.25 μM evodiamine; 4: 0 μM evodiamine; Bcl-2: B cell
lymphoma/lewkmia-2; Bax: Bcl-2-associated Xprotein; PRAP: poly (ADP-ri-
bose)polymerase;GAPDH:glyceraldehyde-3-phosphatedehydrogenase.
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Evodiamine induced the inactivation of PI3K/Akt
pathway
The PI3K/Akt pathway is important for cell growth,
proliferation, and survival.10 To further establish the ef-
fect of evodiamine on PI3K/Akt signaling, the levels of
PI3K, p-PI3K, Akt, and p-Akt proteins in HO-
8910PM cells exposed to the indicated concentrations
of evodiamine for 24 h were evaluated via Western blot
analysis. The low levels of PI3K, p-PI3K, Akt, and
p-Akt were observed as compared with the control
group (P < 0.05, Figures 4A-4C).
MAPK pathways were involved in the
pharmacological action of evodiamine
Under environmental stress, the MAPK family mem-
bers are crucial for cell maintenance.11 To investigate
whether MAPKs were involved in the pharmacological
action of evodiamine, the expressions of ERK1/2MAPK,
p38 MAPK, and SAPK/JNK signaling kinases were ex-
amined. The result demonstrated that the evodiamine
treatment reduced the expression of ERK1/2 MAPK
(P < 0.05, Figures 5A and 5B), instead of p38 MAPK
and SAPK/JNK (P > 0.05, Figure 5A and 5C). Phos-
phorylation was directly linked to kinase activity. Thus,
we also analyzed the expression of the phosphorylated
forms of these MAPKs. We found a significant de-
crease in the expression of p-ERK1/2 and p-p38 after
evodiamine treatment (P < 0.05, Figures 5A to 5C),
but p-SAPK/JNK was less sensitive to the alkaloid than
the other kinases, and thus, the data was not listed.
DISCUSSION
Ovarian cancer is one of the most common gynecolog-
ic cancers. Its 5-year survival rate is poor, despite the
availability of routine surgery and chemotherapy be-
cause of tumor recurrence and metastasis. Thus, the de-
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Figure 4 Effect of evodiamine on PI3K/Akt signaling
A: after treatment with evodiamine (at 0 μM to 5 μM) for 24 h,
Western blot assay was used to detect the expression of
PI3K, Akt, and their phosphorylation in HO-8910PM cells. B:
the data represent the percentage of PI3K and phos-
pho-PI3K. C: the data represent the percentage of Akt and
phospho-Akt. 1: 0 μM evodiamine; 2: 1.25 μM evodiamine; 3:
2.5 μM evodiamine; 4: 5 μM evodiamine; PI3K: phosphati-
dylinositol 3-kinase; p-PI3K: phospho-PI3K. Akt: protein ki-
nase B; p-Akt: phospho-Akt; GAPDH: glyceraldehyde-3-phos-
phate dehydrogenase. Compared with the control group,
the significance levels in the treated groups were aP < 0.05,
bP < 0.001, and cP < 0.01.
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Figure 5 Effect of evodiamine on MAPK signaling
A: after treatment with evodiamine (at 0 μM to 5 μM) for 24 h,
the levels of ERK1/2, phospho-ERK1/2, p38 and phos-
pho-p38 were examined via Western blot analysis. B: the da-
ta represent the percentage of ERK1/2 and phospho-ERK1/2
in HO-8910PM cells. C: the data represent the percentage of
p38 and phospho-p38 in HO-8910PM cells. 1: 0μM evodi-
amine; 2: 1.25μM evodiamine; 3: 2.5μM evodiamine; 4: 5μM
evodiamine. ERK1/2: extracellular signal-regulated protein
kinases; p-ERK1/2: phospho-ERK1/2; p-p38: phospho-p38;
GAPDH: glyceraldehyde-3-phosphate dehydrogenase. Sig-
nificance levels of aP < 0.05 and bP < 0.01 were obtained in
the treatment groups compared with the control group.
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velopment of effective measures against ovarian cancer
is necessary. Evodiamine is a quinolone alkaloid isolat-
ed from a traditional Chinese medicinal plant. Previ-
ous studies have demonstrated that evodiamine can in-
hibit the growth of various tumors. In the present
study, evodiamine exhibited significant antitumor activ-
ity against ovarian cancer cells, and the potential mech-
anisms underlying such activity were explored.
The cell cycle comprises a series of events leading to
cell division and replication to produce two daughter
cells. The cell cycle progression is regulated by cyclins,
cyclin-dependent kinases, and other regulatory pro-
teins.12 The activation of cyclin B1/cdc2 kinase com-
plex is required for the cell to enter the M phase from
the G2 phase.13 Cdc2 is activated via phosphorylation
on Thr161 and dephosphorylation on Thr 14 and
Tyr15 in the late G2 phase, thereby resulting in the ac-
tivation of the cdc2/cyclin B1 complex.14 In this report,
evodiamine induced the accumulation of cells in the
G2/M phase. Western blot analysis showed that the
evodiamine treatment increased the level of cyclin B1,
but the decreased phosphorylation of cdc2 on Tyr15
was not observed. HO-8910PM cells were arrested in
the G2/M phase after evodiamine treatment.
Apoptosis is a programmed cell death process that oc-
curs in abnormal or damaged cells. To examine wheth-
er evodiamine induces apoptosis, the Annexin V-FITC/
PI double staining assay was used. The results showed
that evodiamine caused apoptosis in a dose-dependent
manner. Two key signaling pathways, namely the in-
trinsic and extrinsic pathways, are involved in the in-
duction of apoptosis. The extrinsic pathway is activat-
ed by a death receptor from outside the cell, which in-
directly induces the activation of caspase-8.15 The in-
trinsic pathway is activated by the members of the
Bcl-2 family proteins, including anti-apoptotic pro-
teins, such as Bcl-2, pro-apoptotic proteins (Bax), and
downstream mitochondrial signals (functional cas-
pase-9).15 Evodiamine treatment leads to the cleavage
of caspase-8 and caspase-9, the down-regulation of
Bcl-2, and the up-regulation of Bax. The both path-
ways stimulate the activation of caspase-3 and the
downstream cleavage of PARP. We observed that evodi-
amine activated caspase-3 and induced the degradation
of PARP. Therefore, the extrinsic and intrinsic apopto-
sis pathways might be implicated in evodiamine-in-
duced apoptosis.
MAPK pathways are known to play a role in tumori-
genesis. There are three different MAPK cascades,
namely, ERK1/2 MAPK, p38 MAPK, and SAPK/
JNK. The ERK1/2 MAPK signaling pathway regulates
cell growth, differentiation, proliferation, apoptosis,
and migration functions, and this pathway is often
up-regulated in human tumors.16 Therefore, the specif-
ic blockage of the ERK1/2 MAPK pathway is expected
to result in an anti-proliferative, anti-metastatic, and
anti-angiogenic effects in tumor cells. Our study dem-
onstrated that evodiamine could down-regulate the ex-
pression and activity of ERK1/2 MAPK, as expected.
The p38 MAPK signaling pathways are involved in a
variety of cellular responses, and the outcomes of cellu-
lar response are varied and complicated. The p38
MAPK signaling promotes cell death,17,18 but some re-
ports suggest that p38 MAPK can promote cancer cell
growth and survival.19,20 Our study confirmed that evo-
diamine could reduce the activity of p38 MAPK.
SAPK/JNK is also activated in response to a variety of
cellular and environmental stresses.11 However, evodi-
amine failed to affect the activity of SAPK/JNK in
HO-8910PM cells. The PI3K/Akt pathway plays an
important role in regulating critical cellular functions,
including cell growth and metabolism.10 The study
showed that evodiamine treatment could attenuate the
PI3K/Akt signaling, as expected.
In conclusion, evodiamine can inhibit the growth of
ovarian cancer through G2/M arrest and intrinsic and
extrinsic apoptosis. In addition, PI3K/Akt, ERK1/2
MAPK, and p38 MAPK pathways are involved in evo-
diamine-induced cell death. Therefore, evodiamine
shows therapeutic potential for ovarian cancer treat-
ment. However, further animal studies are required to
validate these findings.
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